Group assigned to receive caffeine for Atrial Fibrillation

Phase-Based Progress Estimates
Texas Cardiac Arrythmia Institute, Austin, TX
Atrial Fibrillation
Intravenous caffeine - Other
All Sexes
What conditions do you have?

Study Summary

This "How caffeine Induces Atrial Tachyarrhythmias" trial will be a multi-center, randomized, double-blinded trial of intravenous caffeine versus placebo among patients undergoing pulmonary vein isolation procedures for Atrial Fibrillation(AF).

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 1 day

1 day
Number of Participants With Atrial Fibrillation Induction
Number of patients with Changes in conduction time
Number of patients with Identification of non-pulmonary triggers of AF
Number of patients with Induction of Atrial Fibrillation/Atrial Tachycardia (AF/AT) or other arrhythmias
Number of patients with Site-specific changes in AERP(Atrial Effective Refractory Period)

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Group assigned to receive caffeine
1 of 2
Group assigned to receive masked placebo
1 of 2
Active Control
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Group assigned to receive caffeine · Has Placebo Group · N/A

Group assigned to receive masked placebo
PlaceboComparator Group · 1 Intervention: Masked Placebo · Intervention Types: Other
Group assigned to receive caffeine
ActiveComparator Group · 1 Intervention: Intravenous caffeine · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 day
Closest Location: Texas Cardiac Arrythmia Institute · Austin, TX
Photo of Austin  1Photo of Austin  2Photo of Austin  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Atrial Fibrillation
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.